News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute
Photo of Robert Jotte from rockymountaincancercenters.com
Jul 1, 2024, 14:03

Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared on LinkedIn:

“Significant advancements in NSCLC treatment! SCRI’s Dr. Robert Jotte presents how Adagrasib shows improvement in PFS and ORR over Docetaxel in previously treated patients. Watch his detailed discussion on ecancer.”

Source: Sarah Cannon Research Institute/LinkedIn

Adagrasib ASCO24 cancer Cancer research clinical trials docetaxel ecancer immunotherapy NSCLC NSCLC treatment OncoDaily Oncology ORR PFS Robert Jotte Sarah Cannon Research Institute
Special Coverage
Blog
Mar 31, 2025, 06:10
The lung cancer patient advocacy sessions at the ELCC 2025 were standout events - Lung Cancer Europe
Insight
Mar 31, 2025, 06:04
Yan Leyfman: Expanding Antibody Therapeutics with TCR Mimicry 
Blog
Mar 31, 2025, 05:50
Jennifer Bires: Proud to speak on AI and mental health at NCCS Cancer Advocacy’s Spring 2025 Cancer Policy Roundtable
Insight
Mar 31, 2025, 05:03
Jarushka Naidoo: My ELCC 2025 Top 3 - MARIPOSA, KRYSTAL7 and Deescalation trials
Blog
Mar 31, 2025, 04:59
Michael Sapienza: Federal funding for cancer and other disease research has been cut by more than $1 billion
Blog
Mar 31, 2025, 04:45
Amil Družić: Excited to be part of the upcoming Young Cancer Professionals Roundtable
Blog
Mar 31, 2025, 03:27
Inside Cancer Careers Podcast Concluding – Thank You to our guests and listeners for two incredible years: Train at NCI
Blog
Mar 31, 2025, 02:59
Ariana Znaor: Consultation period for International Classification of Diseases for Oncology, 4th Edition is extended
Blog
Mar 31, 2025, 02:16
Peter Pisters: Delighted to serve as keynote speaker at Opportunity Austin's quarterly meeting
Blog
Mar 30, 2025, 23:21
Sachin H. Jain: How has "expert bias" mislead you in your work?
Blog
Mar 30, 2025, 22:48
HESI THRIVE 2025 Seed Grant Program - Funding Opportunity for Innovative Cancer Research
Insight
Mar 30, 2025, 21:29
Bishoy Morris Faltas: AI model that predicts response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer